Sector News

Google's ambitious new healthcare biz is hiring

December 10, 2015
Life sciences

The “moonshot” medical device projects at the Google X lab have now become their own spin-off company under Google’s Alphabet parent, with the life sciences business rebranding itself under the name “Verily” this week.

Established a few months ago, the company has a few hundred workers at Google’s Mountain View, CA, campus, as well as small digs in Cambridge, MA, according to the website STAT.

As of Tuesday, Verily’s website linked to about 16 job postings for everything from a clinical research neurologist to a regulatory affairs specialist to a mechanical engineer to a genomics sciences.

Besides chemists and engineers and more, there’s even a philosopher on staff, according to media reports including STAT and Engadget. “We have to understand the ‘why’ of what people do,” Verily CEO Andy Conrad, PhD, formerly chief scientific officer of LabCorp, told STAT.

Verily’s website says the company’s mission is to “bring together technology and life sciences to uncover new truths about health and disease.” It touts life sciences projects that Google has previously disclosed, including efforts to create a glucose-reading contact lens in partnership with Novartis. Joe Jimenez, the CEO of Novartis, has even said there are plans to start testing the “smart” contact lens technology on humans next year.

Indeed, verily is Verily is describing itself as a kind of life sciences innovation factory, using Google’s technological know-how to give the field a boost. A promotional video for the company encourages all types of companies, including traditional medical device companies, to get involved.

“Our multidisciplinary teams have access to advanced research tools, large scale computing power, and unique technical expertise. We work with partners from across the industry and many fields of research to develop new technology, launch studies, and start companies,” the company says on its website.

A recently disclosed U.S. patent application gives a hint that there could be more interesting announcements down the road. The application, filed in 2014, describes a system for needle-free drawing of blood.

Another recent patent application described a laser ablation device with an active tracking system that allows the laser to work even when a patient is moving. Such a surgical laser device could prove helpful when it comes to the partnership Google forged early this year with Johnson & Johnson’s Ethicon subsidiary to advance the field of surgical robotics

Chris Newmarker is senior editor of Qmed and MPMN. Follow him on Twitter at @newmarker.

Source: QMED

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”